[Defining new therapeutic scenarios for oritavancin: severe bacteremic Staphylococcus aureus skin and soft tissue infection in a severely immunocompromised oncology patient]

Rev Esp Quimioter. 2023 Dec;36(6):645-647. doi: 10.37201/req/055.2023. Epub 2023 Oct 11.
[Article in Spanish]
No abstract available

Keywords: Oritavancin; Staphylococcus aureus; bacteremia; immunosuppressed patient; skin and soft tissues.

Publication types

  • Letter

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Glycopeptides / therapeutic use
  • Humans
  • Lipoglycopeptides / therapeutic use
  • Methicillin-Resistant Staphylococcus aureus*
  • Neoplasms* / drug therapy
  • Soft Tissue Infections* / complications
  • Soft Tissue Infections* / drug therapy
  • Staphylococcal Infections* / drug therapy
  • Staphylococcus aureus

Substances

  • oritavancin
  • Lipoglycopeptides
  • Anti-Bacterial Agents
  • Glycopeptides